Close Menu

IVF

By Justin Petrone
British array firm BlueGnome this month relocated to new headquarters to keep pace with growth that has seen it double most of activities in the past year.

Cambridge, UK-based BlueGnome made the acquisition to carve out a bigger piece of the pre-implantation, genetic-diagnostic market. The firm "aims to address diagnosis of single-gene disorders using SNP-array technology," according to its CEO.

The new firm, founded to take advantage of a "rapidly growing" market for pre-implantation genetic screening services, will directly offer BlueGnome's 24Sure platform to in vitro fertilization centers in Europe.

The results not only have the potential to improve the chances of pregnancy for couples undergoing IVF, but also point toward opportunities for research and diagnostic testing of single cancer cells and stem cells, according to a Rubicon official.

The company will use the money to accelerate the global launch of its metabolomics-based procedure for enhancing in vitro fertilization outcomes.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.